CLINICAL_TRIALS
trial_result
· 2019-05-01
Clinical Trial Update: Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing [Phase 2]
Summary
Phase 2 clinical trial of romosozumab for tibial diaphyseal fractures after intramedullary nailing has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Fracture Healing | Phase 2 | Status: COMPLETED | Results posted: 2019-05-01